SpaceX could soon become a top-10 holding in the S&P 500, giving index fund investors significant exposure.

Research and Development Expenses -- $24.6 million, rising by $5.5 million due to ongoing ReMEDy2 trial, global clinical team ...

One dominates globally with billions in free cash flow; the other accelerates U.S. growth with a lean drive-thru model. Their financial paths diverge sharply.